PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC
Preclinical Activity Support DLL3-TOPAbody in DLL3-Expressing SCLC and Other Tumors
DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors
Siglec-15 Represents Potential Therapeutic Target in NSCLC, Other Solid Tumors
